Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Rituximab (anti-CD20 monoclonal antibody) has shown to improve symptoms in rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). An anti-CD20 monoclonal antibody (Reditux™) developed by Dr. Reddy’s Laboratories, India, is currently approved for use both in rheumatology and oncology patients. This retrospective report evaluates the efficacy and safety data from the real-world use of Reditux™ over a 6-month period in Indian patients with RA. All consecutive moderate to severe RA patients who failed therapy with at least two DMARDs including methotrexate (MTX) for 6 months, TNFα inhibitor naive, and willing to take Reditux™ were included. They were prescribed two doses of 1 g Reditux™, at least 15 days apart, with continued stable doses of methotrexate. Efficacy and safety after 24 weeks relative to baseline was assessed using various health assessment variables. A total of 39 patients (mean age of 46 years; 67.5 % females) treated with Reditux™ were evaluated. Statistically significant differences were observed in mean changes of DAS28-CRP, DAS28-ESR, SDAI, HAQ and Patient Global Assessment scores from baseline to 24 weeks (p < 0.0001 for all). Average steroid use per week also significantly reduced at 24 weeks (p = 0.0002). There was no significant gender difference. Mean changes in SDAI, HAQ and Patient Global Assessment scores for patients on steroids were significantly different from those not on steroids (p < 0.05 for all). At 24 weeks, 97 % of patients achieved ACR20 response demonstrating the efficacy of Reditux™ treatment. The treatment was well tolerated by patients without any clinically relevant serious adverse events over 24 weeks. Though limited by number of patients and retrospective in nature, this analysis serves as a real-world evidence of efficacy and safety of Dr. Reddy’s rituximab (Reditux™) in the treatment of csDMARD-failed patients with RA over a 6-month period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP, RESET Investigators (2011) Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial. J Rheumatol 38(12):2548–2556

    Article  CAS  PubMed  Google Scholar 

  2. Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11(Suppl 1):S1

    Article  PubMed  PubMed Central  Google Scholar 

  3. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Rituximab Consensus Expert Committee et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(6):909–920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Edwards JCW, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    Article  CAS  PubMed  Google Scholar 

  5. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806

    Article  CAS  PubMed  Google Scholar 

  6. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5):1390–1400

    Article  CAS  PubMed  Google Scholar 

  7. Lopez-Olivo MA, Tayar JH, Suarez-Almazor ME (2011) The updated guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50(12):2153–2154

    Article  CAS  Google Scholar 

  8. Bukhari M, Abernethy R, Deighton C et al (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50(12):2311–2313

    Article  Google Scholar 

  9. McGonagle D, Tan AL, Madden J, Taylor L, Emery P (2008) Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology 47:865–867

    Article  CAS  PubMed  Google Scholar 

  10. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, Collinson N, Shaw TM, MIRROR Trial Investigators (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49(9):1683–1693

    Article  CAS  Google Scholar 

  11. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (study evaluating rituximab's efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69(9):1629–1635

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM, IMAGE Investigators (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1):39–46

    Article  CAS  PubMed  Google Scholar 

  13. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R (2014) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):529–535

    Article  CAS  PubMed  Google Scholar 

  14. Dr. Reddy’s launches Reditux™—monoclonal antibody treatment for nonHodgkin’s lymphoma. 2007 Apr 30. [Online]. [Accessed 20 April 2015]. Available from: http://www.drreddys.com/media/popups/apr30_2007.htm

  15. Roy PS, John S, Karankal S et al (2013) Comparison of the efficacy and safety of rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol 34(4):292–298

    Article  PubMed  PubMed Central  Google Scholar 

  16. Developing biosimilars in emerging markets: regulatory and clinical considerations. White paper. http://www.ppdi.com. Accessed Aug 2013

  17. Smolen JS, Landewé R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509

    Article  CAS  PubMed  Google Scholar 

  18. Biswas G, Parikh PM, Nair R et al (2006) Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience. J Assoc Physicians India 54:29–33

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr Hetal Shah from Arkus Research Pvt. Ltd., Ahmedabad, India, for her professional support in drafting this manuscript.

Author information

Authors and Affiliations

  1. Apollo Gleneagles Hospital, 58, Canal Circular Road, Kolkata, 700054, West Bengal, India

    Manjeet Bhati & Syamasis Bandyopadhyay

  2. 101-A, Jodhpur Park, Kolkata, 700068, West Bengal, India

    Syamasis Bandyopadhyay

Authors
  1. Manjeet Bhati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Syamasis Bandyopadhyay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syamasis Bandyopadhyay.

Ethics declarations

The protocol for data collection and analysis received the Institutional Ethics Committee’s approval.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhati, M., Bandyopadhyay, S. Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. Clin Rheumatol 35, 1931–1935 (2016). https://doi.org/10.1007/s10067-016-3332-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-016-3332-8

Keywords

Search

Navigation